Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curaleaf HoldingsCURLF +0.40%73 Capex-to-Operating-Cash-Flow is 0.55 as of Jun. 2026, which is 41% below its 10-year median of 0.93. GuruFocus rates CURLF with a GF Score™ of 73/100 and a GF Value™ of $8.20 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 551 Drug Manufacturers companies, Curaleaf Holdings ranks worse than 58.98% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Curaleaf Holdings Capex-to-Operating-Cash-Flow Related Terms
Curaleaf Holdings Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CURLF vs ZTS: Capex-to-Operating-Cash-Flow Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings Capex-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.55 mean?
Curaleaf Holdings (CURLF) has a Capex-to-Operating-Cash-Flow of 0.55 as of Jun. 2026. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Curaleaf Holdings and its competitors. This is 41% below median its historical median of 0.93. Over the past decade, Curaleaf Holdings' Capex-to-Operating-Cash-Flow has ranged from 0.47 to 10.22. According to the industry distribution chart, Curaleaf Holdings ranks #325 out of 551 companies in the Drug Manufacturers industry, placing it in the top 59%.
Is Curaleaf Holdings' Capex-to-Operating-Cash-Flow too high?
Curaleaf Holdings' current Capex-to-Operating-Cash-Flow of 0.55 is 41% below median its 10-year median of 0.93. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 10.22. The Drug Manufacturers industry median Capex-to-Operating-Cash-Flow is 0.36. Curaleaf Holdings' value of 0.55 is 52.8% above this industry median. Based on the distribution chart, Curaleaf Holdings ranks #325 out of 551 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Curaleaf Holdings has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' Capex-to-Operating-Cash-Flow compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #325 out of 551 companies for Capex-to-Operating-Cash-Flow. This places Curaleaf Holdings in the lower half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.36. Curaleaf Holdings' value of 0.55 is 52.8% above this benchmark. Historically, Curaleaf Holdings' own Capex-to-Operating-Cash-Flow has ranged from 0.47 to 10.22 over the past decade. While the company's 10-year median is 0.93 vs. the industry median of 0.36, Curaleaf Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Drug Manufacturers company?
The median Capex-to-Operating-Cash-Flow among Drug Manufacturers companies is 0.36, based on 551 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current Capex-to-Operating-Cash-Flow of 0.55 is 52.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median Capex-to-Operating-Cash-Flow is 0.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current Capex-to-Operating-Cash-Flow is 0.55, which is 41% below median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.20, compared to a current price of $9.96 — trading 21.5% above its estimated fair value. The current Capex-to-Operating-Cash-Flow is 0.55, which is 41% below median its 10-year median of 0.93 and 52.8% above the Drug Manufacturers industry median of 0.36. Curaleaf Holdings' overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For Curaleaf Holdings (CURLF), the current Capex-to-Operating-Cash-Flow is 0.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLF) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $9.96 is trading 21.5% above its estimated GF Value™ of $8.20.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for CURLF:
Capex-to-Operating-Cash-Flow: 0.55 (41% below median its 10-year median of 0.93)
GF Value™: $8.20 vs. price of $9.96 (21.5% above fair value)
Industry Position: 52.8% above the Drug Manufacturers median (#325 of 551)
No single metric tells the full story. See the CURLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
73GF Score
Get the complete analysis for CURLF
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLF has been successfully added to your 
